Dividend Coverage: Johnson & Johnson has raised its Dividend for 54 Consecutive Years; Will Trade Ex-Dividend on August 25, 2017

LONDON, UK / ACCESSWIRE / August 24, 2017 / Pro-Trader Daily takes a closer look at Johnson & Johnson (NYSE: JNJ) as the Company’s stock will begin trading ex-dividend on August 25, 2017. In order to capture the dividend payout, investors must purchase the stock a day prior to the ex-dividend date that is by latest at the end of the trading session on August 24, 2017. Are you looking for research on dividend stocks, if so register with us now for your free membership at:

http://protraderdaily.com/register/

Today, PRO-TD covers ex-dividend news on JNJ. Get our free coverage by signing up at:

http://protraderdaily.com/optin/?symbol=JNJ

Dividend Declared

On July 17, 2017, Johnson & Johnson announced that its Board of Directors has declared a cash dividend for Q3 2017 of $0.84 per share on its common stock. The dividend is payable on September 12, 2017, to shareholders of record at the close of business on August 29, 2017. The ex-dividend date is August 25, 2017.

Johnson & Johnson’s indicated dividend represents a yield of 2.52%, which is approximately four times compared to the average dividend yield of 0.66% for the Healthcare sector. The Company has raised its dividend for 54 consecutive years.

Dividend Insights

Johnson & Johnson has a dividend payout ratio of 46.8%, which means that the Company distributes approximately $0.47 for every $1.00 earned. The dividend payout ratio reflects how much money a Company is returning to shareholders versus how much money it is keeping on hand to reinvest in growth, to pay off debt, and/or to add to its cash reserves.

According to analysts’ estimates, Johnson & Johnson is forecasted to report earnings of $7.73 for the next year which is more than double the Company’s annualized dividend of $3.36.

Johnson & Johnson’s cash and cash equivalents were $12.6 billion at the end of the fiscal second quarter of 2017 compared with $19.0 billion at the end of FY16. The primary sources of cash were approximately $8.7 billion net cash generated from operating activities offset by $13.2 billion used by investing activities and $2.1 billion used by financing activities. In addition, the Company had $0.3 billion in marketable securities at the end of Q2 2017 and $22.9 billion at the end of 2016. The Company’s strong financial position indicates its ability to absorb any fluctuations in earnings and cash flow and to sustain its dividend distribution for a long period.

Recent Development for Assurant

On August 21, 2017, Janssen Pharmaceutical Companies of Johnson & Johnson announced that new data from the landmark Phase-3 COMPASS study evaluating the use of XARELTO® (rivaroxaban) in coronary and peripheral artery disease (CAD and PAD) are among the 25 presentations from Janssen Research & Development, LLC and its development partner Bayer to be featured at the ESC Congress 2017 in Barcelona, Spain.

In addition to two late-breaking presentations from the COMPASS study, the companies will present sub-analyses from PIONEER AF-PCI, a study of XARELTO® in patients with non-valvular atrial fibrillation (NVAF) following percutaneous coronary intervention (PCI) with stenting.

Janssen announced earlier this year that COMPASS was being stopped early due to efficacy based on the recommendation of the study’s independent Data Monitoring Committee (DMC), as the primary efficacy endpoint had reached its pre-specified criteria for superiority.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures and sells various products in the health care field worldwide. The Company markets its products to the general public, retail outlets and distributors, wholesalers, hospitals, and health care professionals for prescription use as well as for use in the professional fields by physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1885 and is based in New Brunswick, New Jersey.

Stock Performance

At the closing bell, on Wednesday, August 23, 2017, Johnson & Johnson’s stock dropped 1.41%, ending the trading session at $132.80. A total volume of 5.13 million shares have exchanged hands. The Company’s stock price rallied 4.15% in the last three months, 9.12% in the past six months, and 11.19% in the previous twelve months. Moreover, the stock surged 15.27% since the start of the year. The stock is trading at a PE ratio of 22.46 and has a dividend yield of 2.53%. The stock currently has a market cap of $357.54 billion.

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charter holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily

ReleaseID: 473627